Stock trading up on news
WEST CHESTER, Pa., Aug. 25 /PRNewswire/ -- Cephalon, Inc. (Nasdaq:CEPH) announced today that it has received U.S. Patent Number 5,650,407
covering the composition CEP-2563 and the method for using the compound in pathological conditions of the prostate. The patent expires in 2015. Cephalon also has corresponding patent applications pending worldwide.
Cephalon is investigating CEP-2563 and certain related compounds for the potential treatment of various cancers, including prostate cancer, in collaboration with TAP Holdings Inc. TAP is evaluating CEP-2563's pharmacokinetic and safety profile in patients with advanced cancer.
Cephalon, Inc., headquartered in West Chester, PA, is an international biopharmaceutical company that discovers, develops and markets products to treat neurological disorders. The company is developing products for the treatment of ALS, narcolepsy, peripheral neuropathies, Alzheimer's disease and stroke, and currently copromotes three products in the United States for the treatment of neurological conditions.
This news release may contain forward-looking statements that involve risks and uncertainties. A full discussion of Cephalon's operations and financial condition, including factors that may affect the company's business and future prospects, is contained in documents the company files with the SEC, such as
form 10-Q and 10-K reports. These documents identify important factors that could cause the company's actual performance to differ from current expectations.
SOURCE: Cephalon, Inc. |
